Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Revenues Rise in Q4; Net Loss Remains Flat

NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen Biosystems today reported increased revenues, along with stable losses and R&D expenses, for the last quarter of 2003.


Revenues for the quarter were $15.2 million, up from $13.6 million during the same period in 2002.


R&D expenses totaled $6.1 million, almost the same as during the year-ago period.


The company's net loss for the quarter stayed stable at $6.7 million, or $.23 per share, compared to $6.7 million, or $.25 per share, during the same quarter a year ago.


As of Dec. 31, Ciphergen had cash and investments of $47.3 million.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.